Clear All
11465 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
71288-0147-50 71288-0147 Pemetrexed disodium Pemetrexed 750.0 mg/30mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Dec 13, 2022 In Use
61703-0161-05 61703-0161 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intramuscular, Intrathecal, Intravenous, Subcutaneous Nov 4, 2024 In Use
46708-0730-36 46708-0730 METHOTREXATE METHOTREXATE 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Jun 4, 2024 In Use
00469-1425-21 00469-1425 Gilteritinib Xospata 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral Apr 30, 2022 In Use
00469-1425-90 00469-1425 Gilteritinib Xospata 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral Nov 29, 2018 In Use
00078-0698-19 00078-0698 RYDAPT Rydapt 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral Apr 28, 2017 In Use
00078-0698-99 00078-0698 RYDAPT Rydapt 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral Apr 28, 2017 In Use
65597-0504-28 65597-0504 QUIZARTINIB VANFLYTA 17.7 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral Jul 20, 2023 In Use
00078-0698-51 00078-0698 RYDAPT Rydapt 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral Apr 28, 2017 In Use
65597-0511-04 65597-0511 QUIZARTINIB VANFLYTA 26.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral Jul 20, 2023 In Use
00078-0698-02 00078-0698 RYDAPT Rydapt 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral Apr 28, 2017 In Use
65597-0504-04 65597-0504 QUIZARTINIB VANFLYTA 17.7 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral Jul 20, 2023 In Use
65597-0511-28 65597-0511 QUIZARTINIB VANFLYTA 26.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral Jul 20, 2023 In Use
59676-0050-28 59676-0050 Erdafitinib BALVERSA 5.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral Apr 12, 2019 In Use
59676-0040-28 59676-0040 Erdafitinib BALVERSA 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral Apr 12, 2019 In Use
59676-0040-56 59676-0040 Erdafitinib BALVERSA 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral Apr 12, 2019 In Use
59676-0030-84 59676-0030 Erdafitinib BALVERSA 3.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral Apr 12, 2019 In Use
59676-0030-56 59676-0030 Erdafitinib BALVERSA 3.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral Apr 12, 2019 In Use
50881-0027-01 50881-0027 Pemigatinib PEMAZYRE 9.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Oral Apr 17, 2020 In Use
50881-0028-01 50881-0028 Pemigatinib PEMAZYRE 13.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Oral Apr 17, 2020 In Use
50881-0026-01 50881-0026 Pemigatinib PEMAZYRE 4.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Oral Apr 17, 2020 In Use
64842-0120-06 64842-0120 FUTIBATINIB LYTGOBI 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral Feb 3, 2023 In Use
64842-0120-04 64842-0120 FUTIBATINIB LYTGOBI 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral Feb 3, 2023 In Use
64842-0120-05 64842-0120 FUTIBATINIB LYTGOBI 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral Feb 3, 2023 In Use
72730-0202-01 72730-0202 infigratinib TRUSELTIQ 75.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral May 28, 2021 In Use

Found 11465 results — Export these results